China’s first online-only insurance agency ZhongAn announced on Monday the terms for the largest and most anticipated IPO of China’s tech scene in the second half of this year. The company plans to issue 199 million new shares at HK$53.70 ($6.88) to HK$59.70 apiece for an up to HK$11.9 billion ($1.5 billion) IPO on the Hong Kong Stock Exchange.

Of the total shares, 95% will be offered globally while 5% offered for public subscription in Hong Kong, according to the firm. Trading of the shares will start from September 28th.

Becoming a cornerstone investor in the company, SoftBank Group plans to purchase 72 million shares, or a 5% stake in ZhongAn at the offer price. That means SoftBank Group’s stake would be worth about $522 million.

Founded in 2013, ZhongAn is a joint venture among Alibaba, Tencent and Chinese insurance company PingAn. The firm offers insurance products and solutions for consumer finance, health, automobile and travel services. It’s also planning to add life insurance and other health products after the IPO.

ZhongAn says it has sold over 7.2 billion insurance policies and served over 492 million customers since its inception and claims to be China’s largest insurer in by the number of customers and policies sold.

Alibaba’s financial affiliate Ant Financial is ZhongAn’s biggest shareholder with a 16% stake, according to a preliminary prospectus filed in June. PingAn Insurance Group and Tencent each hold 12% of ZhongAn. In 2015, ZhongAn raised RMB 5.8 billion from a group of investors including Morgan Stanley and China International Capital Corp, CDH Investments, and SAIF Partners. The fundraising valued it at about $8 billion at the time.

Reuters, citing a source close to the matter, reports that the institutional portion of ZhongAn’s IPO is oversubscribed. Representatives for ZhongAn declined to comment.

Emma Lee is Shanghai-based tech writer, covering startups and tech happenings in China and Asia in general. We are looking for stories related to tech and China. Reach her at

Leave a comment

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.